Researchers have discovered that the mutation and inactivation of a normally protective enzyme may facilitate the metastatic spread of medulloblastoma.
Researchers have uncovered why WNT medulloblastoma is notably responsive to chemotherapy – a finding that could lead to improved treatments for other types of brain cancer.
Study finds proton beam therapy has potential to treat pediatric brain cancer with fewer severe and longer-term side effects compared with conventional photon radiotherapy.
New preclinical study has demonstrated that DNA repair enzyme Dicer could be a novel therapeutic target in medulloblastoma.
A novel combination therapy that could prevent resistance to cytostatics, which are commonly used in the treatment of medulloblastoma, has been discovered.
This article offers an interesting perspective on the challenge of managing brain tumors in teenagers and young adults.
Researchers have reported a link between the genomes of cells that originate in the neural crest and tumor development, which may open up doors for novel ways to diagnose and treat cancer.
Varying molecular defects linked to DDX3X gene mutations may help develop individualized therapy in medulloblastoma
A study from St Jude Children’s Research Hospital suggests that differing molecular defects linked to mutation of the DDX3X gene may provide a foundation for the development of more individualized treatments in pediatric medulloblastoma patients.
A preclinical study published recently in Developmental Cell has identified a protein that is vital to both normal brain development and in numerous cases, the development of medulloblastoma.
Researchers from Newcastle University (UK) and The Institute of Cancer Research (London, UK) have identified the unique genetic pathways that lead to childhood medulloblastoma relapse.